PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial

Trial Profile

PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs PSMA 617 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms PERCIST; RESIST-PC
  • Most Recent Events

    • 25 Sep 2018 Planned primary completion date changed from 12 Jul 2018 to 31 Dec 2018.
    • 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top